Table 4 Significantly enriched KEGG pathways after Clo exposure
Term | Count | PValue | Benjamini | FDR |
|---|---|---|---|---|
ECM-receptor interaction | 12 | 8.28E-05 | 1.15E-02 | 0.098 |
Valine, leucine and isoleucine degradation | 9 | 1.15E-04 | 7.99E-03 | 0.135 |
Cardiac muscle contraction | 11 | 2.31E-04 | 1.07E-02 | 0.273 |
Arginine and proline metabolism | 9 | 3.19E-04 | 1.11E-02 | 0.376 |
Glycolysis/Gluconeogenesis | 10 | 3.74E-04 | 1.04E-02 | 0.441 |
Hypertrophic cardiomyopathy (HCM) | 11 | 4.27E-04 | 9.92E-03 | 0.503 |
Focal adhesion | 17 | 8.40E-04 | 1.67E-02 | 0.987 |
Dilated cardiomyopathy | 11 | 8.86E-04 | 1.54E-02 | 1.040 |
Alzheimer's disease | 16 | 9.98E-04 | 1.54E-02 | 1.171 |
Huntington's disease | 16 | 1.06E-03 | 1.47E-02 | 1.238 |
Oxidative phosphorylation | 13 | 1.21E-03 | 1.53E-02 | 1.418 |
Parkinson's disease | 13 | 1.48E-03 | 1.71E-02 | 1.727 |
Propanoate metabolism | 6 | 2.80E-03 | 2.98E-02 | 3.260 |
Citrate cycle (TCA cycle) | 6 | 3.26E-03 | 3.21E-02 | 3.774 |